Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection

Late 2013, the first indigenous cases of chikungunya have been observed in the French Antilles. At the end of May 2014, almost all of the islands of the Caribbean were affected by the outbreak.

During the large epidemic which affected the Island of La Réunion in 2005/2006, the attack rate was 38%. The most active period was three months.

In this context, knowledge of the attack rate and the epidemic in the Caribbean is an important issue for outbreak management and modeling work.

As the chikungunya virus had never circulated in the Caribbean, determining the seroconversion rate can be achieved by realizing a seroprevalence survey among the general population at the end of the outbreak. Another simple method is to estimate the rate in a cohort of patients followed regularly and whose habitat is distributed throughout the territory studied.

The follow up of patients infected by the human immunodeficiency virus (HIV) in the French West Indies is almost exclusively performed in hospitals in department of Infectious and Tropical Diseases.The high prevalence of HIV and homogeneous distribution of infected patients on all of our territories, allow to hypothesize that the risk of transmission of arboviruses by exposure to mosquito bites is comparable to the general population. This patient cohort is well suited to study the emergence of Chikungunya in the French West Indie .

Primary objective :

To estimate the cumulative incidence at the end of the first Chikungunya outbreak in the French West Indies by estimating the prevalence of specific antibodies of chikungunya virus in a sample (randomly constituted) from patients infected by HIV and representative of the general population of Martinique and Guadeloupe

Secondary objective :

To estimate the frequency of asymptomatic infections by the chikungunya virus in the studied population To estimate the frequency of chronic forms of chikungunya in the studied population

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Alphavirus Infections Arbovirus Infections Blood-Borne Infections Chikungunya Fever Chikungunya Virus Infection Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Mosquito-Borne Diseases RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Togaviridae Infections Urogenital Diseases Vector Borne Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Guadeloupe, Pointe à Pitre, Guadeloupe, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult (> 18 years old)
Followed for HIV infection at the 2 investigators centers (1 located at Martinique and 1 at Guadeloupe)
resident in Martinique /Guadeloupe ( French West Indies)
informed consent signed by the patient

Exclusion criteria

patient who lived more than 6 month in an risk area for chikungunya virus infection
patient with or documented chronic rheumatism
patient who has received a blood transfusion during year 2013 or patient who is supposed to receive a blood transfusion during the study
patient who has planned to live outside French West Indies during the follow up period

Treatment and study plan

Biological sample collection

Other

A blood sample is collected during a follow up visit for HIV infection.

Primary outcomes

Presence or not of chikungunya virus-specific immunoglobulin G antibodies (Elisa test)

Time frame: 1 day

Presence or not of chikungunya virus-specific immunoglobulin G antibodies

Secondary outcomes

Change From Baseline in Pain

Time frame: 6 , 12 , 18 months after the first symptoms of chikungunya virus infection

Score range from 0 (No pain) to 10 (worst possible pain)

Sponsors and collaborators

Lead sponsor

University Hospital Center of Martinique

Other

Registry information

Acronym: ChikVIH

Important dates

Study start: 2015
Primary completion: 2015
Study completion: 2016
First posted: Sep 17, 2015
Registry last updated: Jul 26, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed